At the time of writing, Supernus Pharmaceuticals Inc [SUPN] stock is trading at $43.32, up 1.50%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SUPN shares have gain 2.73% over the last week, with a monthly amount glided 31.39%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Supernus Pharmaceuticals Inc [NASDAQ: SUPN] stock has seen the most recent analyst activity on July 30, 2025, when Cantor Fitzgerald upgraded its rating to a Overweight but kept the price target unchanged to $42 for it. Previously, Cantor Fitzgerald downgraded its rating to Neutral on February 19, 2025, and dropped its price target to $36. On January 06, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $57 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $36 on September 11, 2024. In a note dated April 13, 2021, Jefferies upgraded an Buy rating on this stock and boosted its target price from $25 to $40.
For the past year, the stock price of Supernus Pharmaceuticals Inc fluctuated between $29.16 and $43.73. Currently, Wall Street analysts expect the stock to reach $42 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $43.32 at the most recent close of the market. An investor can expect a potential drop of -3.05% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
According to Supernus Pharmaceuticals Inc [NASDAQ:SUPN], the company’s sales were 665.12M for trailing twelve months, which represents an -1.71% plunge. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.06 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.81 points at the first support level, and at 42.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.68, and for the 2nd resistance point, it is at 44.05.
Ratios To Look Out For
It is important to note that Supernus Pharmaceuticals Inc [NASDAQ:SUPN] has a current ratio of 2.58. In addition, the Quick Ratio stands at 2.43 and the Cash Ratio stands at 0.51. Considering the valuation of this stock, the price to sales ratio is 3.65, the price to book ratio is 2.29 and price to earnings (TTM) ratio is 37.86.
Transactions by insiders
Recent insider trading involved Sensenig Bethany, Director, that happened on Aug 14 ’25 when 5369.0 shares were sold. Director, Hudson Frederick M. completed a deal on Aug 14 ’25 to sell 7457.0 shares. Meanwhile, Director FREDERICK M HUDSON bought 7457.0 shares on Aug 14 ’25.
